Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
22
DRIO Quote, Financials, Valuation and Earnings
Last price:
$10.97
Seasonality move
:
-6.68%
Day range:
$10.27 - $11.77
52-week range:
$5.94 - $17.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.71x
P/B ratio:
0.33x
Volume:
60.1K
Avg. volume:
13.5K
1-year change:
-19.62%
Market cap:
$24.7M
Revenue:
$27M
EPS (TTM):
-$12.39
Analysts' Opinion
-
Consensus RatingDarioHealth Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, DarioHealth Corp. has an estimated upside of 74.93% from its current price of $10.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $10.29.
Fair Value
-
According to the consensus of 4 analysts, DarioHealth Corp. has 74.93% upside to fair value with a price target of $18.00 per share.
DRIO vs. S&P 500
-
Over the past 5 trading days, DarioHealth Corp. has underperformed the S&P 500 by -8.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
DarioHealth Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
DarioHealth Corp. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter DarioHealth Corp. reported revenues of $5M.
Earnings Growth
-
DarioHealth Corp. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter DarioHealth Corp. reported earnings per share of -$3.05.
Enterprise value:
24.2M
EV / Invested capital:
--
Price / LTM sales:
5.71x
EV / EBIT:
--
EV / Revenue:
0.98x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.90x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.1M
Return On Assets:
-24.99%
Net Income Margin (TTM):
-115.29%
Return On Equity:
-41.55%
Return On Invested Capital:
-28.66%
Operating Margin:
-189.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $23.5M | $23.1M | $24.7M | $7.4M | $5M | |
| Gross Profit | $8.6M | $9.2M | $14.1M | $3.9M | $3M | |
| Operating Income | -$50.5M | -$59.5M | -$39.7M | -$12M | -$9.5M | |
| EBITDA | -$45.4M | -$52.7M | -$34.1M | -$9.9M | -$8.9M | |
| Diluted EPS | -$2.05 | -$0.97 | -$12.39 | -$0.25 | -$3.05 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $59.2M | $71.6M | $56.2M | $29.5M | $42.2M | |
| Total Assets | $117.2M | $126.3M | $106.5M | $110M | $117.7M | |
| Current Liabilities | $12.7M | $11.5M | $8.1M | $18.8M | $9.3M | |
| Total Liabilities | $12.7M | $37.4M | $38.5M | $51.4M | $42.8M | |
| Total Equity | $104.4M | $88.9M | $68M | $58.5M | $74.9M | |
| Total Debt | $66K | $24.9M | $29.8M | $29.9M | $31.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31M | -$39.2M | -$26.8M | -$7.4M | -$7.4M | |
| Cash From Investing | -$523K | -$9M | -$137K | -$32K | -$41K | |
| Cash From Financing | $18.5M | $20.2M | $42.7M | -- | $17.4M | |
| Free Cash Flow | -$31.5M | -$39.4M | -$26.9M | -$7.4M | -$7.4M | |
DRIO
Sector
Market Cap
$24.7M
$24.1M
Price % of 52-Week High
57.99%
49.1%
Dividend Yield
0%
0%
Shareholder Yield
-102.49%
-1.67%
1-Year Price Total Return
-19.62%
-21.71%
Beta (5-Year)
1.161
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.32
200-day SMA
Sell
Level
$12.45
Bollinger Bands (100)
Sell
Level
10.35 - 14.65
Chaikin Money Flow
Sell
Level
-291K
20-day SMA
Sell
Level
$11.12
Relative Strength Index (RSI14)
Sell
Level
42.34
ADX Line
Buy
Level
14.04
Williams %R
Neutral
Level
-75.1773
50-day SMA
Sell
Level
$11.48
MACD (12, 26)
Sell
Level
-0.45
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
1.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.327)
Sell
CA Score
(Annual)
Level (-2.2745)
Sell
Beneish M-Score
(Annual)
Level (-1.7477)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.146)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, DRIO has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DRIO average analyst price target in the past 3 months is $18.00.
-
Where Will DarioHealth Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that DarioHealth Corp. share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About DarioHealth Corp.?
Analysts are divided on their view about DarioHealth Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DarioHealth Corp. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is DarioHealth Corp.'s Price Target?
The price target for DarioHealth Corp. over the next 1-year time period is forecast to be $18.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DRIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for DarioHealth Corp. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DRIO?
You can purchase shares of DarioHealth Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DarioHealth Corp. shares.
-
What Is The DarioHealth Corp. Share Price Today?
DarioHealth Corp. was last trading at $10.97 per share. This represents the most recent stock quote for DarioHealth Corp.. Yesterday, DarioHealth Corp. closed at $10.29 per share.
-
How To Buy DarioHealth Corp. Stock Online?
In order to purchase DarioHealth Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DRIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DRIO
Sector
P/E ratio
--
23.23x
PEG ratio
0.00x
-0.01x
P/B ratio
0.33x
1.75x
Price / LTM sales
5.71x
1.50x
Growth Metrics
DRIO
Sector
Revenue growth
-32.55%
3.24%
Earnings growth
-1144.19%
10.12%
Revenue (5-year growth)
29.04%
6.27%
Earnings forecast
-$1.59
-$0.19
Profitability
DRIO
Sector
Profitability FY 2024
$13.3M
$2.7M
Return on invested capital
-28.66%
-33.65%
Return on assets
-24.99%
-29.68%
Return on equity
-41.55%
-38.98%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
12
Balance Sheet
DRIO
Sector
Total cash
$32.1M
$25M
Short term investments
$697K
$23.9M
Total assets
$118.9M
$72.5M
Long term debt
$31.2M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 29x
Alerts
Buy
73
NKTR alert for Feb 11
Nektar Therapeutics [NKTR] is up 21.04% over the past day.
Buy
53
ICHR alert for Feb 11
Ichor Holdings Ltd. [ICHR] is up 2.63% over the past day.
Sell
26
MEDP alert for Feb 11
Medpace Holdings, Inc. [MEDP] is down 3.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
